NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

December 2009 Targets in Oncology Updates and Additions

  • ABL1
  • Breakpoint cluster region (BCR)
  • Fms-like tyrosine kinase 3 (FLT3, FLT-3)
  • Gastrin-releasing-peptide (GRP) receptor (GRPr)
  • Mammalian target of rapamycin (mTOR)
  • Mitogen-activated protein kinase kinase 1 (MAP2K1)
  • Mitogen-activated protein kinase kinase 1 (MAP2K1)
  • Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA)
  • V-raf murine sarcoma viral oncogene homolog B1 (BRAF)
  • Wnt

 

 

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM